Chemical inhibitors of DHX33 include a variety of compounds that target different aspects of its enzymatic activity, primarily focusing on the ATPase and RNA helicase functions. Adenosine 5'-triphosphate disodium can directly compete for ATP binding sites on DHX33, which are indispensable for the protein's helicase activity. By occupying these sites, the compound effectively inhibits the ATPase function critical for the unwinding of RNA substrates, a primary role of DHX33. Similarly, Enoxacin and Flavopiridol attack the same ATPase domain, with Enoxacin directly interfering with ATP hydrolysis and Flavopiridol binding to the ATP-binding pocket. Both mechanisms result in the inhibition of DHX33's ability to manipulate RNA structures, which is necessary for its role in RNA metabolism.
Additionally, Aurintricarboxylic acid inhibits DHX33 by a different mechanism, blocking the protein's ability to bind RNA, which is a prerequisite for helicase activity. This binding is also impeded by Myricetin, which intercalates with the RNA substrate, preventing DHX33 from accessing the RNA it needs to unwind. Nucleotide analogs like 5'-Guanylyl imidodiphosphate and Ribavirin interfere with the GTP binding and hydrolysis, with 5'-Guanylyl imidodiphosphate serving as a non-hydrolyzable GTP analog and Ribavirin mimicking guanosine nucleotides, both leading to an inhibition of the GTPase activity essential for DHX33 function. On the other hand, compounds like 2'-Deoxyadenosine 5'-triphosphate and 7-Deazaadenosine compete with ATP, which is indispensable for the catalytic action of DHX33's helicase domain, thereby inhibiting its function. Lastly, general ATPase inhibitors like Suramin and Sodium orthovanadate nonspecifically obstruct the ATP binding required for enzymatic activity, while BX-795, although primarily a kinase inhibitor, blocks the ATP binding site crucial for DHX33's helicase action. Each of these chemicals acts to inhibit the enzymatic activity of DHX33, thereby inhibiting the protein's function in RNA processing and metabolism.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aurintricarboxylic Acid | 4431-00-9 | sc-3525 sc-3525A sc-3525B sc-3525C | 100 mg 1 g 5 g 10 g | $20.00 $31.00 $47.00 $92.00 | 13 | |
Aurintricarboxylic acid can inhibit DHX33 by preventing the protein from binding to RNA substrates, which is essential for its helicase activity, thereby inhibiting its function in RNA metabolism. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
Ribavirin can inhibit DHX33 by mimicking the guanosine nucleotide, thereby interfering with the enzymatic processes that require GTP binding and hydrolysis, which are crucial for DHX33's helicase function. | ||||||
Enoxacin | 74011-58-8 | sc-205670 sc-205670A | 500 mg 1 g | $39.00 $48.00 | 2 | |
Enoxacin inhibits DHX33 by binding to its ATPase domain and interfering with ATP hydrolysis, which is a critical step in DHX33's RNA helicase activity. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin can inhibit DHX33 by non-specifically binding to the protein's nucleotide-binding domain, which can block ATP binding and hydrolysis, thus inhibiting its helicase function. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 targets the ATP-binding kinase domain, and while it is primarily used for kinase inhibition, it can inhibit DHX33 by blocking its ATP binding site, which is essential for the helicase's ATPase activity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits DHX33 by binding to the ATP-binding pocket, which is crucial for the ATPase and helicase activities of DHX33, thus blocking its function in RNA metabolism. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
Sodium orthovanadate can act as a general ATPase inhibitor and can inhibit DHX33 by competing with ATP, preventing its hydrolysis which is necessary for the helicase activity of DHX33. | ||||||
Tubercidin | 69-33-0 | sc-258322 sc-258322A sc-258322B | 10 mg 50 mg 250 mg | $184.00 $663.00 $1958.00 | ||
7-Deazaadenosine can inhibit DHX33 by mimicking adenosine and competing with ATP for binding to the ATPase domain, which is essential for the catalytic helicase activity of DHX33. | ||||||
Myricetin | 529-44-2 | sc-203147 sc-203147A sc-203147B sc-203147C sc-203147D | 25 mg 100 mg 1 g 25 g 100 g | $95.00 $184.00 $255.00 $500.00 $1002.00 | 3 | |
Myricetin can inhibit DHX33 by intercalating with the RNA substrate, thus preventing the RNA from binding to DHX33 which is necessary for its RNA helicase function. | ||||||